Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Adjuvant Pomegranate Juice Intake Improves the Inflammatory Status of Hospitalized Covid-19 Patients: A Randomized and Placebo-Controlled Trial Publisher Pubmed



Yousefi M1 ; Sadriirani M1 ; Mahmoodi S1 ; Samimi B1 ; Pourmahmoudi A1 ; Hosseinikia M1 ; Sadeghi O2 ; Roustaei N8 ; Saeedinezhad Z3 ; Espin JC4 ; Ansari S7 ; Panahande SB1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Nutrition, School of Health and Nutrition, Yasuj University of Medical Sciences, Yasuj, Iran
  2. 2. Food Security Research Center, Department of Community Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran
  3. 3. Department of Internal Medicine, School of Medicine, Yasuj University of Medical Sciences, Yasuj, Iran
  4. 4. Food & Health Lab
  5. 5. Quality, Safety, and Bioactivity of Plant Foods
  6. 6. CEBAS-CSIC, 30100 Campus de Espinardo, Murcia, Spain
  7. 7. Department of Nursing, School of Nursing, Yasuj University of Medical Sciences, Yasuj, Iran
  8. 8. Department of Biostatistics and Epidmiology, School of Health and Nutrition, Yasuj University of Medical Sciences, Yasuj, Iran

Source: Complementary Therapies in Medicine Published:2023


Abstract

Background: This study aimed to evaluate the effect of pomegranate juice intake on the inflammatory status and complete blood count in hospitalized Covid-19 patients. Methods: This randomized, double-blinded placebo-controlled trial included 48 patients with two parallel arms. In addition to the standard care provided at the hospital, the patients consumed 500 mL of whole pomegranate juice (PJ) daily or a placebo for 14 days. Inflammatory markers (C-reactive protein (CRP), interleukin-6 (IL-6), erythrocyte sedimentation rate (ESR)) and complete blood count were determined at baseline and after the 14 days of intervention. Results: At the end of the intervention, a significant decreased was observed in primary outcomes [mean difference (95 %CI)] including IL-6 [5.24(0.87–9.61)], CRP [23.19(11.93–34.44)] and ESR [10.52(1.54–19.50)] in the PJ group vs. before the intervention. In addition, significant changes were also observed in the some of the secondary outcomes, including neutrophils, lymphocytes, platelets, platelets-to-lymphocyte(PLR) and neutrophils-to-lymphocyte (NLR) ratios (p < 0.05) in the PJ group compared to before the intervention. At the end of the intervention period, the mean change of IL-6 [− 7.09(−12.21 to − 1.96)], white blood cells [− 3.09(− 6.14 to − 0.05)], neutrophils [− 9.12(−18.08 to −0.15)], lymphocyte [7.05(0.17–13.92)], platelets [− 94.54(− 139.33 to − 49.75)], PLR [− 15.99(− 29.31 to − 2.67)], blood oxygen saturation [1.75(0.13–3.37)] and MCV [0.31(− 0.25 to 0.88)] levels were significantly different between groups while no difference was observed between the two groups in other blood indices. Conclusion: Our results suggest that pomegranate juice intake might slightly improve the inflammatory status and CBC outcomes of COVID-19 patients and it may be beneficial. © 2023 The Authors
Experts (# of related papers)
Other Related Docs
17. Epidemiology, Virology, Clinical Features, Diagnosis, and Treatment of Sars-Cov-2 Infection, Journal of Experimental and Clinical Medicine (Turkey) (2021)
32. Pomegranate Consumption and Blood Pressure: A Review, Current Pharmaceutical Design (2017)
38. Cytokines and Micrornas in Sars-Cov-2: What Do We Know?, Molecular Therapy Nucleic Acids (2022)
46. Cancer Care Management During the Covid-19 Pandemic, Risk Management and Healthcare Policy (2020)
49. Corticosteroid Therapy for 2019 Novel Coronavirus: Lessons From Sars and Mers, Avicenna Journal of Clinical Microbiology and Infection (2021)